MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia

References

• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:vi50–vi54.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Di Renzo N, Brugiatelli M, et al. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:223–228.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516–2522.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Seiffert M, Dietrich S, Jethwa A, et al. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1023–1031.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775.
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177–1184.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• Balatti V, Pekarky Y, Croce CM. Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol. 2015;8:12
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Fathullahzadeh S, Khanmohammadi R, et al. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J Cell Physiol. 2018;233:888–900.
   PubMed Web of Science ®Google Scholar
• Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20:1603–1614.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008;68:5540–5545.
   PubMed Web of Science ®Google Scholar
• Ma H, Pan JS, Jin LX, et al. MicroRNA-17 ∼ 92 inhibits colorectal cancer progression by targeting angiogenesis. Cancer Lett. 2016;376:293–302.
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008;105:12885–12890.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4:e5532.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 2010;3:347.
   PubMedGoogle Scholar
• Ohyashiki K, Umezu T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One. 2011;6:e16408
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kontos CK, Tsiakanikas P, et al. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. Leuk Res.2018;70:1–7.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kontos CK, Diamantopoulos MA, et al. MicroRNA-155-5p overexpression in peripheral blood mononuclear cells of chronic lymphocytic leukemia patients is a novel, independent molecular biomarker of poor prognosis. Dis Markers. 2017;2017:1.
   Google Scholar
• Kontos CK, Papageorgiou SG, Diamantopoulos MA, et al. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. Leuk Res. 2017;53:65–73.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos MA, Kontos CK, Kerimis D, et al. Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. Clin Chem Lab Med. 2017;55:737–747.
   PubMed Web of Science ®Google Scholar
• Adamopoulos PG, Kontos CK, Papageorgiou SG, et al. KLKB1 mRNA overexpression: a novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. Clin Biochem. 2015;48:849–854.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–1108.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259.
   PubMed Web of Science ®Google Scholar
• Kotaki R, Koyama-Nasu R, Yamakawa N, et al. miRNAs in normal and malignant hematopoiesis. Int J Mol Sci. 2017;18.
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–2261.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838.
   PubMed Web of Science ®Google Scholar
• Vasilatou D, Papageorgiou SG, Kontsioti F, et al. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes. Leuk Res. 2013;37:251–258.
   PubMed Web of Science ®Google Scholar
• Smith L, Baxter EW, Chambers PA, et al. Down-regulation of miR-92 in breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS One. 2015;10:e0139698.
   PubMed Web of Science ®Google Scholar
• Song Y, Li J, Zhu Y, et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 2014;5:11669–11680.
   PubMedGoogle Scholar
• Chen Y, Kingham K, Ford JM, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 2011;18:2594–2598.
   PubMed Web of Science ®Google Scholar
• Chen T, Zhou Q, Tang H, et al. miR-17/20 controls prolyl hydroxylase 2 (PHD2)/hypoxia-inducible factor 1 (HIF1) to regulate pulmonary artery smooth muscle cell proliferation. J Am Heart Assoc. 2016;5.
   Web of Science ®Google Scholar
• Li S, Moffett HF, Lu J, et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011;6:e16956.
   PubMed Web of Science ®Google Scholar
• Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119:521–529.
   PubMed Web of Science ®Google Scholar
• Wan Y, Wu CJ. SF3B1 mutations in chronic lymphocytic leukemia. Blood. 2013;121:4627–4634.
   PubMed Web of Science ®Google Scholar
• Swords R, Bruzzi J, Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome. Med Oncol. 2007;24:17–32.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kontos CK, Pappa V, et al. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. Oncologist. 2011;16:1280–1291.
   PubMed Web of Science ®Google Scholar
• Kontos CK, Adamopoulos PG, Papageorgiou SG, et al. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. Clin Chem Lab Med. 2016;54:315–324.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Van Damme M, Crompot E, et al. Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia. Mol Med. 2015;21:123–133.
   PubMed Web of Science ®Google Scholar
• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62.
   PubMed Web of Science ®Google Scholar